滚动资讯
Novo NordiskNovo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - simplywall.stEurofinsEurofins Scientific SE Stock (FR0014000MR3): stock in focus after quiet trading week - AD HOC NEWSCell桥状蛋白VPS13A与翻转酶XK介导的脂质转移机制Cell格雷戈里·J·汉农（1964–2026）FierceBiotech礼来公布23亿美元收购Ajax后的首批临床数据：JAK抑制剂“一出手就见效”Eli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - investor.lilly.comEli LillyLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - PR NewswireEli LillyLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ - Fierce BiotechEli LillyAbridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion - Healthcare DiveEndpoints News生物制药2025年行业薪酬报告；Parabilis创下行业IPO纪录；更多资讯Clinical OMICs长读长DNA检测或可替代15种现有罕见病检测方法10x Genomics Blog10x Genomics (TXG) 近期回报激增后的股票估值分析 - simplywall.st

资讯库

最新 最旧 清除
@JINHUA YIDI MEDICAL APPLIANCE CO.LTD
总数 7
来源 JINHUA YIDI MEDICAL APPLIANCE CO.LTD
搜索 --